Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

This early Eli Lilly study, titled “A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide,” tests how kidney disease changes the way the drug moves through the body. It focuses on safety and drug exposure in people with severe renal issues and in people with normal kidney function.

Eloralintide (LY3841136) is an injectable drug given under the skin in a single dose. The goal is to see if patients with chronic kidney disease or end stage kidney disease can receive this treatment safely, and whether dosing may need to change for these groups.

The trial is interventional with parallel groups, where different sets of patients receive the same drug but have different kidney function levels. It is non-randomized and open label, so both doctors and patients know they are getting Eloralintide, and the main aim is basic science rather than direct treatment benefit.

The study started after first submission on February 17, 2026, and each participant is expected to be followed for about 14 weeks. A key milestone is the primary completion date, when main data on drug exposure and safety will be collected, with full completion to follow and the record last updated on March 12, 2026.

For investors, this update signals that Lilly continues to broaden its pipeline beyond headline obesity and diabetes assets, with work in complex kidney patients who are often under treated. Success here could support premium pricing, strengthen Lilly’s renal and metabolic franchise, and add to its long term growth story, while also raising the bar for peers like Novo Nordisk and other metabolic players.

The study remains active and recruiting, and investors can track further updates and detailed protocol changes on the ClinicalTrials.gov portal.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.

Disclaimer & DisclosureReport an Issue